Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03178825
Other study ID # DIVACIP002
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 19, 2017
Est. completion date February 25, 2020

Study information

Verified date August 2020
Source Sciton
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This multi-center clinical trial will evaluate the safety and long-term efficacy of hybrid fractional 2940 nm and 1470 nm lasers for treatment of symptoms of Genitourinary Syndrome of Menopause.


Description:

Both 2940 nm Er:YAG (Erbium-doped yttrium aluminium garnet) and 1470 nm diode lasers are cleared by the Food and Drug Administration (FDA) for ablation, vaporization, coagulation of soft tissue and for skin resurfacing. Fractional delivery of laser is a well-established method that stimulates tissue remodeling in the dermis while leaving the surrounding tissue intact in order to decrease healing time. The layers of skin and vaginal mucosal tissue exhibit similarities that suggest the clinical results seen with skin resurfacing may be translated to the vaginal tissue. Improved vaginal tissue health may lead to improvement of symptoms of Genitourinary Syndrome of Menopause (GSM). This multi-centered, 18-month prospective clinical trial will evaluate the safety and long-term effectiveness of hybrid fractional 2940 nm and 1470 nm lasers (HFL) as an alternative non-surgical, non-hormonal treatment for symptoms of GSM.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date February 25, 2020
Est. primary completion date February 25, 2020
Accepts healthy volunteers No
Gender Female
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria:

1. Healthy biological female aged between 40 to 70 years

2. Is post-menopausal with a AND b OR c

1. No menses for at least 12 months

2. Follicle-stimulating hormone (FSH) level over 40mlU/mL

3. Has had a bilateral oophorectomy at least 12 months ago with no hormone replacement

3. Is experiencing at least two self-reported symptoms of GSM, such as

1. Vaginal irritation in absence of infection

2. Chronic burning sensation

3. Chronic itching in the absence of infection

4. Recurring urinary tract infections (UTIs)

5. Vaginal dryness during sexual activity

6. Pain during sexual activity (dyspareunia)

4. Has been experiencing symptoms of GSM for greater than 3 months

5. Is unable due to medical contraindication or unwilling to receive hormone-based vaginal therapy

6. Normal and up-to-date pap smear if applicable

7. Is sexually active (i.e. intravaginal intercourse) or has the potential and desire to be sexually active if symptoms of GSM improve

8. Can read, understand and sign informed consent form

Exclusion Criteria:

1. Undiagnosed abnormal genital bleeding

2. Has history of pelvic surgery or other energy-based vaginal therapy within 6 months prior to enrollment

3. Previous use of topical estrogen therapy within the last 3 months

4. Has used vaginal creams, moisturizers, lubricants or homeopathic preparations or received anticoagulants, antiplatelet, thrombolytic, vitamin E or anti-inflammatory within 2 weeks of treatment

5. History of heart failure

6. Has equal to or greater than stage III prolapse, according to pelvic organ prolapse quantification system (POP-Q)

7. Has an active sexually transmitted infection (STI)

8. Has signs or symptoms of vaginitis/vulvitis

9. Has signs or symptoms of acute urinary tract infection (UTI)

10. Has participated in any clinical trial involving an investigational drug or procedure within the past 30 days

11. The investigator feels that for any reason the subject is not eligible to participate in the study

Study Design


Intervention

Device:
Hybrid Fractional Laser
Consecutive and coincident fractional 2940 nm and 1470 nm lasers

Locations

Country Name City State
United States Carolinas Healthcare System Charlotte North Carolina
United States Women's Pelvic Health Institute Los Gatos California
United States Louisiana State University New Orleans Louisiana
United States The Female Pelvic Medicine Institute of Virginia North Chesterfield Virginia
United States Coyle Institute Pensacola Florida
United States Woodlands Gynecology & Aesthetics The Woodlands Texas

Sponsors (1)

Lead Sponsor Collaborator
Sciton

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in Vaginal Maturation Index (VMI) An objective assessment of vaginal hormone response as well as overall hormonal environment by calculating a ratio of parabasal cells, intermediate cells, and superficial cells 12 months
Secondary Change from baseline in Histology Change from baseline in epithelial thickness, collagen, elastin, vascularity, and fibroblast density. 12 months
Secondary Change from baseline in Vaginal Health Index Score (VHIS) A quantitative assessment of vaginal health that evaluates vaginal elasticity, fluid volume, pH, epithelial integrity, and moisture on a scale of 1 to 5. 12 months
Secondary Change from baseline in Female Sexual Function Index (FSFI) A multidimensional self-report instrument for assessment of female sexual function. 12 months
Secondary Change from baseline in Day-to-Day Impact of Vaginal Aging Questionnaire (DIVA) A multidimensional self-report measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. 12 months
Secondary Change from baseline in Clinical Photography Change from baseline in the appearance of the treatment area. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05039775 - Clitoral Therapy Device in Alleviating Sexual Dysfunction After Genital Mutilation. N/A
Recruiting NCT05380856 - Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction N/A
Not yet recruiting NCT05918770 - Side Effects Screening and Early Intervention to Impact in Quality of Life of Gynaecological Cancer Patients N/A
Completed NCT02430987 - Low Sexual Desire and Metabolic Syndrome N/A
Completed NCT02096783 - Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer N/A
Completed NCT02837796 - Effects of Trans-Obturator Tape outside-in Versus Inside-out Procedure for Stres Urinary Incontinence N/A
Completed NCT01660152 - Vacuum Erection Device in Improving Recovery of Erectile Function in Patients With Prostate Cancer Undergoing Surgery N/A
Completed NCT01434290 - Radiation Therapy in Treating Patients With Prostate Cancer Phase 2
Active, not recruiting NCT00981305 - Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors Phase 3
Completed NCT04964895 - Sexual Quality of Patients After Bladder Cancer Cystectomy N/A
Enrolling by invitation NCT05832268 - Pelvic Floor Function After Obstetric Injury to the Anal Sphincter
Completed NCT04066218 - Sexual Function Screening in Childhood Cancer Survivors
Not yet recruiting NCT05530681 - Correlation Pelvic Floor Function and Ultrasound Findings One Year After Childbirth N/A
Recruiting NCT05826691 - Benign Prostate Surgery and QOL and Sexual Function
Completed NCT04560283 - HYDEAL-D® Application for Promoting the Restoration of Sexual Function in the Postpartum Period Phase 4
Completed NCT03232801 - A Mindfulness-based Intervention for Older Women With Low Sexual Desire N/A
Suspended NCT04544735 - Improving Women's Function After Pelvic Radiation N/A
Completed NCT05732844 - Efficacy of the Use of Vaginal Balls for the Improvement of Urinary Incontinence and Sexual Function in Women. N/A
Recruiting NCT05097469 - Carbon Dioxide Acupulse Laser Treatment Versus Sham Treatment and Sexual Dysfunction. N/A
Withdrawn NCT01635543 - Investigation of Sexual Function in Crohn's Disease Patients With Perianal Fistulas N/A